



TEXAS STATE BOARD OF PHARMACY

COMPOUNDING ADVISORY GROUP MEETING

Held via Videoconference

Wednesday, September 16, 2020

MINUTES

The meeting was called to order at 9:00 a.m.

Compounding Advisory Group members present via videoconference were Lisa Ashworth, R.Ph.; Jeff Carson, R.Ph.; Steve Hoffart, Pharm.D., R.Ph.; Jim Hrnecir, R.Ph.; Jobby John, Pharm.D., R.Ph.; Cole Knutson, R.Ph.; Amanda Lawrence, Pharm.D., R.Ph.; Jasper Lovoi, Pharm.D., R.Ph.; Pamella Ochoa, Pharm.D., R.Ph.; Richie Ray, R.Ph.; Genee Schexnayder, Pharm.D., R.Ph.; Ray Solano, R.Ph.; and Kelly Tran, Pharm.D., R.Ph. Board Member Liaison Donna Montemayor, R.Ph., was not in attendance.

Board staff present via videoconference were Allison Vordenbaumen Benz, R.Ph., M.S., Executive Director; Kerstin Arnold, General Counsel; Megan Holloway, Deputy General Counsel; Iona Grant, R.Ph., Senior Compliance Officer; Jim Clark, R.Ph., Compliance Officer; and Keya Henry, Ph.T.R., Compliance Inspector.

Following introductions, Ms. Benz reviewed the goals of the Compounding Advisory Group. She explained that the Board charged the Compounding Advisory group with reviewing and recommending updates to the inspection and licensure process for compounding pharmacies; and serving as a resource to Board staff by providing guidance on professional standards.

Ms. Benz opened discussion, directing Mr. Carson to moderate.

Ms. Benz recessed the meeting at 10:32 a.m.

Ms. Benz reconvened the meeting at 10:45 a.m.

The group continued discussion.

Ms. Benz recessed the meeting at 12:00 p.m.

Ms. Benz reconvened the meeting at 1:00 p.m.

Following discussion, the group agreed on a definition for a non-sterile pharmacy as a pharmacy that compounds from bulk API, manipulates a preparation beyond its FDA approved use, or manipulates powders in an open system. Additionally, the group requested a way to collaborate and share questions to assist inspectors with inspecting a non-sterile pharmacy to determine if a pharmacy is engaged in non-sterile compounding and to determine if a pharmacy is safely compounding non-sterile preparations. Ms. Benz indicated that board staff would provide a method and instructions on how they group could share those questions. The group also decided to review the non-sterile rules at the next meeting on November 18, 2020.

Ms. Arnold also indicated that the group members could contact her if any of them would like to serve as an expert witness for disciplinary cases involving compounding.

Ms. Benz adjourned the meeting at 3:37 pm.